Pay in 4 interest-free payments of $7.43 Learn more
Ships within 48 hours · Estimated delivery Aug 8 - Aug 13
The CAS registry number for BPC-157 (Body Protection Compound-157) is 137525-51-0
A conservative approach: if BPC-157 is initiated in a patient on a stable SNRI regimen, do not simultaneously adjust the SNRI dose
The STEP 1 trial of once-weekly injectable semaglutide reported substantial average weight loss in adults with obesity, as published in the New England Journal of Medicine
Eden Health has paused its compounded GLP-1 program (both semaglutide and tirzepatide) for new patient enrollment as of mid-2026
Oral BPC-157 may have lower systemic absorption than subcutaneous injection because peptides are partially degraded in the digestive process
Subjects were treated with open-label VYVANSE for at least 26 weeks prior to being assessed for entry into the randomized withdrawal period
